Hylaform Generic Name: hylan b dermal filler gel Brand Name: Hylaform side effects drug center hylaform (hylan b dermal filler gel) drug Related Drugs Perlane Radiesse Recedo Zyderm PROFESSIONAL SIDE EFFECTS Contents Drug Description Indications & Dosage Side Effects & Drug Interactions Warnings & Precautions Overdosage & Contraindications Clinical Pharmacology Medication Guide Drug Description Hylaform® (hylan B) Dermal Filler Gel Federal (USA) law restricts this device to sale by or on the order of a licensed physician, or properly licensed practitioner. BEFORE USING PRODUCT, READ THE FOLLOWING INFORMATION THOROUGHLY. DESCRIPTION Device Description Hylaform (hylan B gel) is a sterile, nonpyrogenic, viscoelastic, clear, colorless gel implant composed of crosslinked molecules of hyaluronan. Hyaluronan is a naturally occurring polysaccharide of the extra-cellular matrix in human tissues, including skin. Indications & Dosage INDICATIONS Intended Use/ Indications Hylaform gel is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). DOSAGE AND ADMINISTRATION Individualization Of Treatment Severely indurated, sharply marginated and very superficial wrinkles may be difficult to distend and, therefore, are difficult to correct. If a defect cannot be distended because of extensive scarring or non-elastic tissue, the course of correction will be prolonged, if correction is achievable. Touch-up implantations may be required in areas with greater motion or mechanical stress (e.g., nasolabial folds). All patients should be counseled to anticipate supplemental implantations to achieve and maintain optimal correction. HOW SUPPLIED Hylaform gel is supplied in individual treatment syringes with needles, and is packaged for single patient use, ready for injection (implantation). The contents of the syringe are sterile and non-pyrogenic. The volume markings on the syringe are for reference only. To Attach Needle To Syringe Peel sealed cover off the needle guard. Remove tip cap from syringe. Attach needle to syringe and twist to secure. To assure proper needle attachment, use the needles provided or 30-gauge needles with similar needle guards. Fully seat hub of needle in syringe. Do not over tighten, as this may break the needle and/or dislodge the syringe. Pull off the needle guard to expose needle. Procedure To Change Needle Peel sealed cover off new needle guard. Twist used needle to disconnect it from the syringe. Attach new needle to syringe and twist to secure. Pull off the needle guard to expose needle. To place an order, contact INAMED Corporation at (800) 624-4261. Instructions For Use Hylaform gel is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). Prior to treatment with Hylaform gel, the patient should be fully apprised of the indications, contraindications, warnings, precautions, treatment responses, adverse reactions, and method of administration. Patients also should be advised that supplemental “touch-up11 implantations may be required to achieve and maintain maximum correction. A complete medical history, including allergies, should be obtained to determine whether the patient is an appropriate candidate for Hylaform treatment. The patient's soft tissue deficiencies should be characterized with regard to etiology, distensibility, stress at the site, and depth of lesion. Depending on the type of skin, best results are obtained when the defect is readily distensible and correction can be visualized by manual manipulation (stretching) of the skin. Pretreatment photographs are recommended. Topical or injectable anesthesia may be used to manage pain during and after injection. After ensuring that the patient has thoroughly washed the treatment area with soap and water, the area should be swabbed with alcohol or other antiseptic. Prior to injecting Hylaform gel, depress the plunger rod until the product flows out of the needle. Hylaform gel is administered using a thin gauge needle (30G ½”) . The injection technique with regard to the angle and orientation of the bevel, the depth of injection, and the quantity administered may vary. A linear threading technique, serial puncture injections, or a combination of the two have been used to achieve optimal results. Subderma! application should be avoided because such application may not provide optimal correction. If Hylaform gel is injected too deep, the duration of the effect will be shorter. If Hylaform gel is injected too superficially this may result in visible lumps and/or discoloration. Inject Hylaform gel applying even pressure on the plunger rod while slowly pulling the needle backwards. The wrinkle should be lifted and eliminated by the end of the injection. It is important that the injection is stopped just before the needle is pulled out of the skin to prevent material from leaking out or ending up too superficially in the skin. Only correct to 100% of the desired volume effect. Do not overcorrect. The degree and duration of the correction depend on the character of the defect treated, the tissue stress at the implant site, the depth of the implant in the tissue and the injection technique. Markedly indurated defects may be difficult to correct. If immediate blanching occurs, the injection should be stopped and the area massaged until it returns to a normal color. When injection is completed, the treated site should be gently massaged so that it conforms to the contour of the surrounding tissues. If an over correction has occurred, massage the area between your fingers or against an underlying superficial bone to obtain optima! results. if the wrinkle needs further treatment, the same procedure should be repeated until a satisfactory result is obtained. With patients who have localized swelling the degree of correction is sometimes difficult to judge at the time of treatment. In these cases, it is better to invite the patient to a touch-up session after 1-2 weeks. Patients may have mild to moderate injection site reactions, which typically resolve in a few days. If the treated area is swollen immediately after the injection, an ice pack can be applied to the site for a short period. After the initial treatment (from 1 to 2 weeks later), an additional treatment of Hylaform gel may be necessary to achieve the desired level of correction. The need for an additional treatment may vary from patient to patient and is dependent upon a variety of factors such as wrinkle severity, skin elasticity and dermal thickness at the treatment site. The physician should instruct the patient to promptly report to her/him any evidence of problems possibly associated with the use of Hylaform gel. Storage Hylaform gel should be stored at room temperature, 2°-30°C (36°-86°F). DO NOT FREEZE. Hyiaform gel has a clear appearance. In the event that a syringe contains material that is not clear do not use the syringe and notify INAMED Corporation immediately at (800) 624-4261. Sterility Hylaform gel is packaged for single patient use. Do not resterilize. Do not use if package is opened or damaged. Manufactured by: Genzyme Biosurgery, 1125 Pleasant View Terrace, Ridgefield, New Jersey 07657 USA. Distributed by: INAMED Aesthetics, 5540 Ekwill Street, Santa Barbara, CA 93111 USA (800) 624-4261 Side Effects & Drug Interactions SIDE EFFECTS Clinical Evaluation of Hylaform Gel In a randomized, controlled clinical trial to evaluate the safety and effectiveness of Hylaform gel as a dermal filler for nasolabial folds, 261 patients 30 to 55 years of age were randomized between the treatment (Hylaform) and the control (Zyplast) implant. During the initial phase of the study, each patient was injected with the respective dermal filler in the nasolabial folds for wrinkle correction. Patients were followed for 12 weeks. Following completion of the initial phase, each of the patients who initially received Hylaform gel treatment was offered repeat treatment with Hylaform products in both nasolabial folds and evaluated for safety for an additional 4 weeks. Initial Treatment Phase Adverse events reported during the 12 weeks following treatment were categorized according to the reported severity (see Table 1). Table 1 : Injection Procedure Related Adverse Events by Maximum Severity Occurring in > 5% of Patients [Number (%) of Patients] Primary System Organ Class/ Preferred Term Hylaform Total Zyplast Total Hylaform N = 133 Zyplast N = 128 Mild Mod* Severe Mild Mod* Severe At least 1 adverse event 111 (84) 109 (85) 105 (79) 6 (5) 0 (0) 105 (82) 2 (2) 2 (2) General disorders and administration site conditions 111 (84) 109 (85) 105 (79) 6 (5) 0 (0) 105 (82) 2 (2) 2 (2) Injection site erythema 84 (63) 86 (67) 83 (62) 1 (1) 0 (0) 85 (66) 1 (1) 0 (0) Injection site bruising 54 (41) 39 (30) 52 (39) 2 (2) 0 (0) 37 (29) 2 (2) 0 (0) Injection site swelling 47(35) 53 (41) 45 (34) 2 (2) 0 (0) 52 (41) 1 (1) 0 (0) Injection site pain 42 (32) 29 (23) 40 (30) 2 (2) 0 (0) 26 (20) 1 (1) 2 (2) Injection site pruritus 10 (8) 11 (9) 10 (8) 0 (0) 0 (0) 11 (9) 0 (0) 0 (0) Injection site desquamation 3 (2) 7 (6) 3 (2) 0 (0) 0 (0) 7 (6) 0 (0) 0 (0) *Mod = Moderate Table 2: Duration of Procedure or Device Related Events Occurring in Greater thaii 5% of Patients Primary System Organ Class/ Preferred Term Hylaform gel n = 133 n (%) Zyplast n = 128 n (%) Duration* ≤ 3 days 4-7 days 8-14 days > 14 days Total ≤ 3 days 4-7 days 8-14 days > 14 days Total Injection site erythema 53 (40) 16 (12) 13 (10) 2 (2) 84 (63) 59 (46) 11 (9) 5 (4) 11 (9) 86 (67) Injection site bruising 19 (14) 23 (17) 10 (8) 2 (2) 54 (41) 10 (8) 21 (16) 5 (4) 3 (2) 39 (31) Injection site swelling 31 (23) 12 (9) 4 (3) 00 47 (35) 38 (30) 12 (9) 00 3 (2) 53 (41) injection site pain 39 (29) 2 (2) 1 (1) 00 42 (32) 22 (17) 5 (4) 1 (1) 1 (1) 29 (23) Injection site pruritus 8 (6) 00 1 (1) 2 (2) 11 (8) 7 (6) 2 (2) 2 (2) 00 11 (9) Injection site desquamation 1 (1) 1 (1) 1 (1) 00 3 (2) 3 (2) 3 (2) 1 (1) 00 7 (6) *Duration refers to number of days irrespective of onset of Adverse Event to the date of the study device implantation Device related adverse events occurred infrequently in both groups and were primarily of mild intensity; 2 patients (2%) experienced 3 events in the Hylaform group, and 9 patients (7%) experienced 14 events in the Zyplast group. The Hylaform device related adverse events were erythema, induration and pruritus. Clinical trial adverse events unrelated to the injection procedure reported in the Hylaform treatment group occurring in greater than 1% of patients (n=133) were nasopharyngitis (5.3%), headache (4.5%), influenza (3.8%), rash (3%), conjunctivitis (1.5%), and sinusitis (1.5%). Repeat Treatment Phase During the initial and repeat treatment phases of the study, hylan B IgG antibody titers were measured at baseline and throughout treatment. Only one patient exhibited a positive antibody response after treatment with hylan B. This patient experienced adverse events of injection site bruising and headache lasting 11 days and 2 days after initial treatment, respectively. These adverse events were not reported as device-related and were not considered to be associated with the increased antibody titer level. None of the other study patients developed similar increases in antibody titer levels during the initial or repeat study phases. Of the 133 patients treated with Hylaform gel during the initial phase, 96 underwent repeat treatment with Hylaform products and were followed for up to 4 weeks for safety. The types of adverse events seen after repeat treatment with Hylaform products were similar to those seen during the initial clinical evaluation. The most frequently reported adverse events included injection site erythema, bruising, swelling, pain, nodules, pruritus and tenderness. Device-related adverse events were reported in 3 patients during repeat treatment with Hylaform gel and included involuntary muscle contraction described as eye fasciculations in one patient and dizziness in another. A third patient experienced bilateral aseptic abscess formation at the site of injection, but did not develop increased hylan B antibody titers throughout either the initial or repeat phase of the study. Surveillance outside the US Hylaform post market safety surveillance in countries outside of the United States indicates that the most frequently reported adverse events include: injection site erythema, nodule, swelling, and induration. These adverse events are similar in frequency and duration to what has been noted during clinical trials. DRUG INTERACTIONS No information provided. Warnings & Precautions WARNINGS Use of Hylaform gel at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present, should be deferred until the underlying process has been controlled. The safety and efficacy of Hylaform gel for use in lip augmentation has not been established. Injection procedure reaction to Hylaform gel has been observed as consisting mainly of short-term inflammatory symptoms starting early after treatment and with less than 7 days duration. Refer to the Clinical Studies section for details. PRECAUTIONS Hylaform gel is packaged for single patient use ready for use. Do not resterilize. Do not use if package is opened or damaged. Based on preclinical studies, patients should be limited to 20 mL of Hylaform gel per 60 kg (130 lbs) body mass per year. The safety of injecting greater amounts has not been established. The safety or effectiveness of Hylaform gel for the treatment of anatomic regions other than nasolabial folds has not been established in controlled clinical studies. Long-term safety and effectiveness of Hylaform gel beyond one year have not been investigated in clinical trials. As with all transcutaneous procedures, Hylaform gel implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed. The safety of Hylaform gel for use during pregnancy, in breastfeeding females or in patients under 18 years has not been established. The safety of Hylaform gel in patients with increased susceptibility to keloid formation, hypertrophic scarring and pigmentation disorders has not been studied. Hylaform gel should not be used in patients with known susceptibility to keloid formation, hypertrophic scarring or pigmentation disorders. Genzyme is conducting a post approval study to determine the likelihood of keloid formation and pigmentation disorders in patients with Fitzpatrick Scale Skin types (V - VI receiving Hylaform injections Hylaform gel should be used with caution in patients on immunosuppressive therapy. Patients who are using substances that can prolong bleeding, such as aspirin, non-steroidal anti-inflammatory drugs and warfarin may, as with any injection, experience increased bruising or bleeding at injection sites. After use, treatment syringes and needles may be potential biohazards. Handle accordingly and dispose of in accordance with accepted medical practice and applicable local, state and federal requirements. Hylaform gel is a clear, colorless gel without particulates. In the event that the content of a syringe shows signs of separation and/or appears cloudy, do not use the syringe and notify INAMED Corporation at (800) 624-4261. The patient should be informed that he or she should minimize exposure of the treated area to excessive sun and UV lamp exposure and extreme cold weather until any initial swelling and redness has resolved. If laser treatment, chemical peeling or any other procedure based on active dermal response is considered after treatment with Hylaform gel there is a possible risk of eliciting an inflammatory reaction at the implant site. This also applies if Hylaform gel is administered before the skin has healed completely after such a procedure. Overdosage & Contraindications OVERDOSE No information provided. CONTRAINDICATIONS Hylaform gel is contraindicated for use in breast augmentation, or for implantation into bone, tendon, ligament, or muscle, Hylaform gel is contraindicated for patients with a history of known hypersensitivity to avian proteins. Hylaform gel must not be injected into blood vessels. Introduction of Hylaform gel into the vasculature may occlude the vessels and could cause infarction or embolization. Clinical Pharmacology CLINICAL PHARMACOLOGY Clinical Studies Study Design A prospective, double blind, randomized, multi-center clinical study was conducted to evaluate the safety and effectiveness of Hylaform gel when used as a dermal filler in the nasolabial folds. Patients were randomized between Hylaform gel and a commercially available control material, Zyplast implant (derived from bovine collagen) and were injected with enough material to achieve desired correction of each nasolabial fold. (Patients enrolled into the study underwent double bovine collagen skin testing.) At 2 weeks touch-up treatment with additional material was allowed, only if patients showed less than a 1-point improvement on the 6-point grading scale (see DESCRIPTION below). The primary efficacy endpoint for the study was the ability to correct nasolabial folds at 12 weeks in comparison to the control material. Correction of nasolabial folds was determined by an independent panel of blinded dermatologists through photographic assessment. Photographs of nasolabial folds were taken prior to treatment and at 3 days, 2, 4, 8, and 12 weeks following treatment. A 6-point grading scale was used to rank wrinkle severity for each photograph in a random, blinded fashion. Additional analyses included the investigator's visual assessment of each patient's nasolabial folds using the 6-point grading scale, and a qualitative assessment of the level of correction by the investigator and by the patient. Table 2 : Demographics and Pretreatment Characteristics of Total Patient Population, N=261 [Number (% of Patients] Gender Tobacco use Male 16 (6.1) Non-smoking 216(82.7) Female 245 (93.9) Smokers 45 (17.2) Ethnicity Sun Exposure (mean) 1.6 hrs/day Caucasian 208 (79.7) African American 5(1.9) Patients With Prior Dermal Treatments 157 (60.1) Asian 9 (3.4) Hispanic 34(13.0) Other 5(1.9) Treatment Material Delivered The mean total volume injected per nasolabial fold was 0.8 mL for patients in the treatment group (Hylaform gel) and 1.1 mL for patients in the control group (Zyplast implant). The mean volume injected was the same for left and right nasolabial folds and was approximately equivalent to the total volume supplied in one syringe of Hylaform gel (0.75 mL) and of Zyplast implant (1.0 mL) for the clinical study. Twenty-two (16.5%) of 133 Hylaform patients and 9 (7.1%) of the 128 Zyplast patients required a touch-up treatment. The mean volume injected for touch-up per nasolabial fold was 0.3 mL for Hylaform patients and 0.5 mL for Zyplast patients. Hylaform Gel Efficacy Hylaform gel was found to be equivalent to the control materia! (Zyplast implant) in the correction of nasolabial folds after 12 weeks using the independent review of photographs. Mean Score Based on 6-Point Grading Scale Blinded Photographic Assessment Pretreatment 12 Weeks after Treatment Hylaform 2.2 2.3 Zyplast 2.3 2.2 Grading scale: 0=No wrinkles, 1=Just perceptible wrinkle, 2=Shallow wrinkles, 3=Moderately deep wrinkle, 4=Deep wrinkle, well-defined edges, 5=Very deep wrinkle, redundant fold Peak treatment effect with one injection of Hylaform gel was observed during the first 2 weeks after treatment. Photographic assessment showed that, on average, patients had returned to baseline in both groups at 12 weeks. However, the secondary endpoints of investigator's visual assessment and a qualitative assessment of correction by the investigator and by the masked patient during the controlled clinical study support the effectiveness of Hylaform and Zyplast at 12 weeks. Mean Score Based on 6-Point Grading Scale Investigator Live Assessment Pretreatment 12 weeks after treatment Hylaform 3.5 2.4 Zyplast 3.5 2.3 Grading scale: 0=No wrinkles, 1 =Just perceptible wrinkle, 2=Shallow wrinkles, 3-Moderately deep wrinkle, 4=Deep wrinkle, well-defined edges, 5=Very deep wrinkle, redundant fold Based on investigator live assessment, 15% of Hylaform patients and 10% of Zyplast patients returned to pretreatment levels at 12 weeks. Medication Guide PATIENT INFORMATION It is recommended that the following information be shared with patients: To report an adverse reaction, phone the Product Support Department, INAMED Corporation, (800) 624-4261. Within the first 24 hours, patients should avoid: Strenuous exercise Extensive sun or heat exposure Alcoholic beverages Exposure to any of the above may cause temporary redness, swelling, and/or itching at the injection sites. Make-up may be applied a few hours post-treatment if no complications are present {e.g. open wounds, bleeding and infection).
